相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis
Takeshi Mochizuki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2018)
RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
Sakae Tanaka et al.
MODERN RHEUMATOLOGY (2018)
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
Kenneth G. Saag et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis
Hayato Kinoshita et al.
MODERN RHEUMATOLOGY (2017)
Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis
Tetsuo Hasegawa et al.
JOINT BONE SPINE (2017)
Novel treatment strategies in rheumatoid arthritis
Gerd R. Burmester et al.
LANCET (2017)
Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis
Georg Schett
MODERN RHEUMATOLOGY (2017)
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis
Katerina Chatzidionysiou et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Jackie L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation
Lynett Danks et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture
K. Ochi et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Rheumatoid arthritis and incident fracture in women: a case-control study
Sharon L. Brennan et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients
Yasunori Omata et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Pathogenic conversion of Foxp3(+) T cells into T(H)17 cells in autoimmune arthritis
Noriko Komatsu et al.
NATURE MEDICINE (2014)
Management of rheumatoid arthritis: the 2012 perspective
Hisashi Yamanaka et al.
MODERN RHEUMATOLOGY (2013)
Osteopetrosis: genetics, treatment and new insights into osteoclast function
Cristina Sobacchi et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Effects of Disease-Modifying Antirheumatic Drugs on Nonvertebral Fracture Risk in Rheumatoid Arthritis: A Population-Based Cohort Study
Seo Young Kim et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
Yukiko Komano et al.
JOURNAL OF RHEUMATOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Robin K. Dore et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Denosumab-Mediated Increase in Hand Bone Mineral Density Associated With Decreased Progression of Bone Erosion in Rheumatoid Arthritis Patients
A. Deodhar et al.
ARTHRITIS CARE & RESEARCH (2010)
Rheumatoid arthritis associated with osteopetrosis
Yuho Kadono et al.
MODERN RHEUMATOLOGY (2009)
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2008)
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17
M. Hashizume et al.
RHEUMATOLOGY (2008)
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction
Kojiro Sato et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis
T. P. van Staa et al.
ARTHRITIS AND RHEUMATISM (2006)
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis
Stephen J. Jarrett et al.
ARTHRITIS AND RHEUMATISM (2006)
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis
NA Sims et al.
ARTHRITIS AND RHEUMATISM (2004)
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis
P Herrak et al.
ARTHRITIS AND RHEUMATISM (2004)
Evolving concepts of rheumatoid arthritis
GS Firestein
NATURE (2003)
Radiographic healing with sustained clinical remission in a patient with rheumatoid arthritis receiving methotrexate monotherapy
S Wassenberg et al.
ARTHRITIS AND RHEUMATISM (2002)
Signaling crosstalk between RANKL and interferons in osteoclast differentiation
Hiroshi Takayanagi et al.
ARTHRITIS RESEARCH & THERAPY (2002)
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
AR Pettit et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
